3 Complex Generics and Oncology Company, Fermentation Ingredients Maker and Global Pharma Group Stocks With a Strong Future Roadmap: Natco Pharma, Concord Biotech and Lupin
- October 29, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Natco Pharma, Concord Biotech and Lupin: ROE of 12.9% to 23.8% and FY22 to FY26 revenue CAGR of 10.7% to 21.0%. Prices as of 27 Oct 2026.
Quick Answer
The three oncology, fermentation and global pharma to watch are Natco Pharma, Concord Biotech and Lupin. Their return on equity ranges from 12.9% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.7% to 21.0%. Lupin has the highest return on equity at 23.8%, while Natco Pharma has the fastest revenue growth at 21.0% a year. Prices are based on the 27 October 2026 close, and this article is educational, not investment advice.
Oncology, fermentation and global pharma let investors follow companies that serve a growing part of the Indian economy. Natco Pharma, Concord Biotech and Lupin cover a complex generics and oncology company, a fermentation ingredients maker and a global pharma group.
This list covers three oncology, fermentation and global pharma with complete current figures: Natco Pharma, Concord Biotech and Lupin. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Oncology, Fermentation and Global Pharma?
Oncology, fermentation and global pharma are listed pharmaceutical companies that focus on complex generics and oncology, make fermentation-based ingredients and operate across branded generics, complex generics and specialty medicines. Their earnings depend on launches, approvals and demand across markets.
Oncology, Fermentation and Global Pharma at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Natco Pharma | 793 | 15,708 | 13.7 | 36.0 | 15.4 | 0.08 |
| Concord Biotech | 1,268.5 | 13,421 | 49.2 | 36.0 | 12.9 | 0.00 |
| Lupin | 1,972.7 | 89,343 | 16.1 | 36.0 | 23.8 | 0.29 |
On valuation, Natco Pharma and Lupin trade at a P/E below the industry P/E, while Concord Biotech trades above it, which reflects the growth the market already expects. Readers comparing oncology, fermentation and global pharma should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Oncology, Fermentation and Global Pharma Have a Strong Roadmap in India?
Oncology, fermentation and global pharma have a strong roadmap in India because demand for complex generics, global sourcing of specialised ingredients and rising healthcare spending keep widening the market for Indian pharmaceutical firms.
- Complex generics. Difficult products carry steadier demand.
- Specialised ingredients. Global drug makers source biopharma inputs.
- Global reach. Approvals open new markets.
Why Natco Pharma Features Among These Oncology, Fermentation and Global Pharma
Among the oncology, fermentation and global pharma on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.
Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.
The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0.
Roadmap: The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
What to watch: Check the timing of key product launches in the US and the contribution from new drug approvals.
Why Concord Biotech Features Among These Oncology, Fermentation and Global Pharma
Among the complex generics, biopharma ingredient and specialty shares on this list, Concord Biotech is a Gujarat-based biopharma company that makes fermentation-based active ingredients such as immunosuppressants, oncology drugs and anti-infectives for global pharma customers.
The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0.
Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore.
Roadmap: The company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.
What to watch: Monitor the pace of new product introductions and the contribution from formulations.
Why Lupin Features Among These Oncology, Fermentation and Global Pharma
Among the three companies on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.
Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%.
In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.
Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.
Natco Pharma vs Concord Biotech vs Lupin on Key Financials
The table below sets the three oncology, fermentation and global pharma side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Natco Pharma | 2,044 | 4,376 | 21.0% | 1,372 | 31.4% |
| Concord Biotech | 736 | 1,107 | 10.7% | 259 | 23.4% |
| Lupin | 16,616 | 29,039 | 15.0% | 5,355 | 18.4% |
Lupin posts the highest return on equity in this group at 23.8%. Lupin has the largest FY26 revenue at Rs 29,039 crore, and Natco Pharma shows the fastest revenue growth with a 21.0% compound annual rate. A useful habit with oncology, fermentation and global pharma is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Oncology, Fermentation and Global Pharma
Every theme carries risks that deserve a check before any decision. For these oncology, fermentation and global pharma, the main points are: Long-term complex generics, biopharma ingredient and specialty shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Pricing pressure. Generic prices can change by market.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter oncology, fermentation and global pharma by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Oncology, Fermentation and Global Pharma
Oncology, fermentation and global pharma reward investors who follow demand trends, order books and margins together. Natco Pharma, Concord Biotech and Lupin each have a clear plan to grow. Based on the 27 October 2026 close, Natco Pharma trades at Rs 793, Concord Biotech at Rs 1,268.5 and Lupin at Rs 1,972.7.
Download the Univest iOS App or Univest Android App to track oncology, fermentation and global pharma, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are oncology, fermentation and global pharma?
Ans. Oncology, fermentation and global pharma are listed pharmaceutical companies that focus on complex generics and oncology, make fermentation-based ingredients and operate across branded generics, complex generics and specialty medicines. Their earnings depend on launches, approvals and demand across markets. This list looks at three of them, Natco Pharma, Concord Biotech and Lupin, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.
Which oncology, fermentation and global pharma are covered in this list?
Ans. This list covers Natco Pharma, Concord Biotech and Lupin. Based on the 27 October 2026 close, Natco Pharma traded at Rs 793, Concord Biotech at Rs 1,268.5 and Lupin at Rs 1,972.7. Their return on equity ranges from 12.9% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.7% to 21.0%.
Why do oncology, fermentation and global pharma have a strong future roadmap in India?
Ans. Oncology, fermentation and global pharma have a strong roadmap in India because demand for complex generics, global sourcing of specialised ingredients and rising healthcare spending keep widening the market for Indian pharmaceutical firms. The main drivers are as follows. Complex generics. Difficult products carry steadier demand. Specialised ingredients. Global drug makers source biopharma inputs. Global reach. Approvals open new markets. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Natco Pharma performed financially?
Ans. Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
How has Concord Biotech performed financially?
Ans. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0. Looking ahead, the company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.
How has Lupin performed financially?
Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
What risks should investors check before buying oncology, fermentation and global pharma?
Ans. Investors should check a few risks before buying oncology, fermentation and global pharma. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of oncology, fermentation and global pharma investment advice?
Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.